Jazz Pharmaceuticals ((JAZZ)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jazz Pharmaceuticals is conducting a study titled An Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. The study aims to evaluate the efficacy and safety of Zanidatamab combined with CisGem (Cisplatin and Gemcitabine) and possibly a PD-1/L1 inhibitor, compared to standard care alone, for treating advanced HER2-positive biliary tract cancer.
The intervention being tested includes Zanidatamab, a drug administered intravenously, combined with Cisplatin and Gemcitabine, and potentially a PD-1/L1 inhibitor like Durvalumab or Pembrolizumab, depending on local regulations. This combination is intended to improve treatment outcomes for patients.
This Phase 3 study is interventional, with a randomized allocation and a parallel intervention model. There is no masking involved, and the primary purpose is treatment, aiming to provide clear insights into the effectiveness of the new combination therapy.
The study began on July 19, 2024, with the latest update submitted on August 19, 2025. These dates are crucial as they indicate the study’s progress and ongoing recruitment status, which is essential for stakeholders tracking the development.
The update on this clinical study could influence Jazz Pharmaceuticals’ stock performance positively, as successful outcomes may enhance their market position in oncology treatments. Investors might also consider the competitive landscape, including other companies developing similar therapies.
The study is currently recruiting, and further details can be accessed on the ClinicalTrials portal.